AGÕæÈ˹ٷ½

Agios Pharmaceuticals, Inc. (AGIO) â€� Form 144

An affiliate has filed a Form 144 to sell up to 11,914 common shares through Morgan Stanley Smith Barney on or about 07/09/2025. The shares have an aggregate market value of $452,631.92 and represent roughly 0.02 % of the company’s 57,915,199 shares outstanding, indicating a very limited effect on the public float.

The seller acquired the shares on the same date via a cash-settled stock-option exercise. In the prior three months the same individual sold 7,000 shares (4,091 on 07/01/2025 and 2,909 on 06/24/2025) for total gross proceeds of $237,341.32.

The filing states that the insider is unaware of any undisclosed material adverse information and is complying with Rule 144 sale restrictions. Given the modest share count involved, the proposed disposition appears to be a routine liquidity move with minimal expected market impact.

Beyond Air held a Special Meeting of stockholders on June 20, 2025, where shareholders approved a significant Reverse Stock Split proposal. Out of 86,369,869 outstanding shares, 48,476,717 shares were represented at the meeting, constituting a quorum.

Key details of the approved proposal:

• Authorizes the Board to implement a reverse stock split within one year
• Split ratio range between 1-for-10 and 1-for-50
• Voting results: 41,924,612 votes in favor, 6,382,862 against, 169,243 abstentions

This strategic move gives the Board flexibility to consolidate shares, potentially improving the company's market position and stock price structure. The strong shareholder support (86.5% of votes cast in favor) demonstrates confidence in the Board's management strategy.

Beyond Air (NASDAQ: XAIR) filed its Form 10-K Annual Report on June 29, 2025. The excerpt supplied consists almost entirely of XBRL taxonomy tags and entity identifiers, with no accompanying financial statements, narrative sections, risk factors, legal proceedings, or management discussion. Because the critical quantitative and qualitative disclosures normally included in a 10-K are absent from the provided content, no material information relevant to investors can be summarized from this excerpt.

Beyond Air (NASDAQ: XAIR) reported several significant developments in this 8-K filing:

Key Events:

• Released financial results for fiscal quarter and year ended March 31, 2025 (detailed results not provided in filing)
• Appointed Robert Goodman to Board of Directors on June 16, 2025 - Qualified as independent director under Nasdaq standards - Notable experience with BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer
• Submitted PMA supplement application to FDA for LungFit PH II, their next-generation therapeutic nitric oxide generator

The company filed two press releases as exhibits (99.1 and 99.2) detailing the financial results and FDA submission respectively. The appointment of Goodman strengthens the board with extensive healthcare industry expertise, while the FDA submission represents a significant regulatory milestone for their therapeutic device development program.